Our world-class experts. Your child’s care team.
Explore Our Research
Exceptional science. Innovative cures.
Give to our mission.
Covid-19 updates and information
When he was just four months old, Weiming was found to have a rare immunodeficiency known as bubble boy disease. Just when it felt like all hope was lost, he came to St. Jude.
Read This Patient's Story
Read our new strategic plan and learn about our bold vision for the future.
Read This Article
We have some of the world's best survival rates for some of the most aggressive cancers.
You could win a house or other great prizes while helping the kids of St. Jude. Find a St. Jude Dream Home Giveaway® near you.
Visit our St. Jude Gift Shop site
What happens when you give the world’s brightest minds the resources to do something remarkable? Cures.
Read the stories of 12 St. Jude cancer survivors who are graduating high school this year with their passions and dreams intact.
Explore HPV cancer prevention program emphasizing need for HPV vaccination
You're invited to virtually explore the halls of St. Jude Children's Research Hospital in Memphis, Tenn.
Read This Story
We share our research with the world, leading a global effort to understand, treat, and defeat pediatric cancer and other life-threatening diseases.
Support our mission in the way that’s right for you.
St. Jude scientists will discuss research on cellular therapies for pediatric cancer and more at the annual meeting.
Big data can cause big problems in rare disease genetics research. Scientists at
St. Jude created a systematic solution to find the inherited genes contributing to rare disease.
St. Jude demonstrate the role of chromatin regulation in cancer’s resistance to EZH2 inhibitors and offer a way to make treatment more effective.
The team looked at a poorly understood form of chronic leukemia, CLPD-NK. The results led the researchers to create a new model of cancer development.
St. Jude are studying antimicrobial compounds called argyrins. Argyrins have shown some success against a bacterium called Pseudomonas aeruginosa.
RMS is the most common soft tissue sarcoma in children. When it recurs after therapy, the survival rate is only 30%.
More Science & Medicine